arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing
Company profile
Ticker
ARWR
Exchange
Website
CEO
Christopher Anzalone
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ARROWHEAD RESEARCH CORP, INTERACTIVE GROUP INC, INTERACTIVE INC
SEC CIK
Corporate docs
Subsidiaries
Arrowhead Madison Inc. • Arrowhead Australia Pty Ltd ...
IRS number
460408024
ARWR stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
19 Mar 24
8-K/A
Departure of Directors or Certain Officers
15 Mar 24
S-8
Registration of securities for employees
28 Feb 24
DEFA14A
Additional proxy soliciting materials
27 Feb 24
8-K
Departure of Directors or Certain Officers
21 Feb 24
10-Q
2024 Q1
Quarterly report
6 Feb 24
8-K
Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
6 Feb 24
ARS
2024 FY
Annual report to shareholders
29 Jan 24
DEFA14A
Additional proxy soliciting materials
26 Jan 24
DEF 14A
Definitive proxy
26 Jan 24
Transcripts
ARWR
Earnings call transcript
2024 Q1
6 Feb 24
ARWR
Earnings call transcript
2023 Q3
7 Aug 23
ARWR
Earnings call transcript
2023 Q2
2 May 23
ARWR
Earnings call transcript
2023 Q1
6 Feb 23
ARWR
Earnings call transcript
2022 Q4
29 Nov 22
ARWR
Earnings call transcript
2022 Q3
5 Aug 22
ARWR
Earnings call transcript
2022 Q2
11 May 22
ARWR
Earnings call transcript
2022 Q1
3 Feb 22
ARWR
Earnings call transcript
2021 Q4
23 Nov 21
ARWR
Earnings call transcript
2021 Q3
6 Aug 21
Latest ownership filings
SC 13G/A
VANGUARD GROUP INC
10 Apr 24
4
James C Hamilton
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
Hongbo Lu
20 Mar 24
3
Hongbo Lu
18 Mar 24
4
Kenneth Allen Myszkowski
8 Mar 24
144
Notice of proposed sale of securities
6 Mar 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
Christopher Richard Anzalone
2 Feb 24
144
Notice of proposed sale of securities
31 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 110.89 mm | 110.89 mm | 110.89 mm | 110.89 mm | 110.89 mm | 110.89 mm |
Cash burn (monthly) | (no burn) | (no burn) | 36.33 mm | 17.20 mm | 8.42 mm | 12.82 mm |
Cash used (since last report) | n/a | n/a | 240.62 mm | 113.89 mm | 55.76 mm | 84.94 mm |
Cash remaining | n/a | n/a | -129.73 mm | -3.00 mm | 55.13 mm | 25.95 mm |
Runway (months of cash) | n/a | n/a | -3.6 | -0.2 | 6.5 | 2.0 |
Institutional ownership, Q3 2023
58.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 252 |
Opened positions | 21 |
Closed positions | 40 |
Increased positions | 89 |
Reduced positions | 94 |
13F shares | Current |
---|---|
Total value | 1.95 tn |
Total shares | 72.95 mm |
Total puts | 153.50 k |
Total calls | 212.70 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 12.84 mm | $345.00 bn |
Vanguard | 10.86 mm | $291.76 bn |
STT State Street | 5.86 mm | $157.54 bn |
FMR | 4.31 mm | $115.78 bn |
JPM JPMorgan Chase & Co. | 2.78 mm | $74.78 bn |
IVZ Invesco | 2.44 mm | $65.64 bn |
Geode Capital Management | 2.22 mm | $59.61 bn |
Rokos Capital Management | 1.68 mm | $45.03 bn |
Credit Suisse | 1.53 mm | $41.08 bn |
NTRS Northern Trust | 1.27 mm | $34.03 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | James C Hamilton | Common Stock | Sell | Dispose S | No | No | 28.03 | 6,000 | 168.18 k | 204,851 |
20 Mar 24 | Hongbo Lu | Common Stock | Buy | Acquire P | No | No | 27.5 | 1,000 | 27.50 k | 33,680 |
19 Mar 24 | Hongbo Lu | Common Stock | Buy | Acquire P | No | No | 28 | 1,000 | 28.00 k | 32,680 |
18 Mar 24 | Hongbo Lu | Common Stock | Buy | Acquire P | No | No | 27.49 | 1,000 | 27.49 k | 31,680 |
6 Mar 24 | Kenneth Allen Myszkowski | Common Stock | Sell | Dispose S | No | No | 35.19 | 40,000 | 1.41 mm | 400,600 |
31 Jan 24 | Anzalone Christopher Richard | Common Stock | Sell | Dispose S | No | Yes | 32.71 | 19,730 | 645.37 k | 3,715,048 |
31 Jan 24 | Anzalone Christopher Richard | Common Stock | Sell | Dispose S | No | Yes | 32.16 | 37,769 | 1.21 mm | 3,734,778 |
31 Jan 24 | Anzalone Christopher Richard | Common Stock | Option exercise | Acquire M | No | Yes | 14.54 | 57,499 | 836.04 k | 3,772,547 |
31 Jan 24 | Anzalone Christopher Richard | Stock Option Common Stock | Option exercise | Dispose M | No | No | 14.54 | 57,499 | 836.04 k | 351,726 |
News
Reported Sunday, Arrowhead Pharmaceuticals Announces New Phase 2 Data Of Plozasiran Published In JAMA Cardiology And Presented At ACC.24
8 Apr 24
NetApp, Zoom Video And 2 Other Stocks Insiders Are Selling
4 Apr 24
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
11 Mar 24
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
1 Mar 24
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $90 Price Target
8 Feb 24
Press releases
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
7 Apr 24
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
1 Apr 24
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
25 Mar 24
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
8 Mar 24
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
4 Mar 24